Related Experiment Video
Updated: Jun 19, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Targeting the mTOR pathway in neuroendocrine tumors
1Robert Wood Johnson University Hospital, and School of Nursing, Rutgers University, Newark, NJ, USA. nancymgardner@msn.com
Abstract:
Neuroendocrine tumors (NETs) are rare, generally indolent tumors that are lethal in the metastatic setting. Treatment options to control tumor growth are limited. In clinical trials, investigational oral mammalian target of rapamycin (mTOR) inhibitors have shown activity in patients with metastatic NETs. The purpose of this article is to provide oncology nurses with a background on the mechanism of action of mTOR inhibitors in the setting of NETs. Increased understanding of the role of mTOR in the pathogenesis of NETs has led to the study of mTOR inhibitor investigational agents in NETs. Treatments are evolving and currently focusing on targeted agents such as mTOR inhibitors. Understanding the mechanisms of action of targeted agents is a critical component of nursing knowledge.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
